- Home
- FTK vs ARVN Comparison
FTK vs ARVN Comparison
Compare FTK & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FTK
- ARVN
- Stock Information
- Founded
- FTK 1985
- ARVN 2015
- Country
- FTK United States
- ARVN United States
- Employees
- FTK N/A
- ARVN N/A
- Industry
- FTK Major Chemicals
- ARVN Biotechnology: Pharmaceutical Preparations
- Sector
- FTK Industrials
- ARVN Health Care
- Exchange
- FTK Nasdaq
- ARVN Nasdaq
- Market Cap
- FTK 437.9M
- ARVN 456.2M
- IPO Year
- FTK N/A
- ARVN 2018
- Fundamental
- Price
- FTK $14.86
- ARVN $7.90
- Analyst Decision
- FTK Buy
- ARVN Buy
- Analyst Count
- FTK 2
- ARVN 21
- Target Price
- FTK $12.00
- ARVN $20.53
- AVG Volume (30 Days)
- FTK 779.3K
- ARVN 1.9M
- Earning Date
- FTK 08-05-2025
- ARVN 07-29-2025
- Dividend Yield
- FTK N/A
- ARVN N/A
- EPS Growth
- FTK 683.07
- ARVN N/A
- EPS
- FTK 0.46
- ARVN N/A
- Revenue
- FTK $202,013,000.00
- ARVN $426,900,000.00
- Revenue This Year
- FTK $16.63
- ARVN $4.26
- Revenue Next Year
- FTK $9.94
- ARVN N/A
- P/E Ratio
- FTK $32.35
- ARVN N/A
- Revenue Growth
- FTK 11.96
- ARVN 498.74
- 52 Week Low
- FTK $3.79
- ARVN $5.90
- 52 Week High
- FTK $16.87
- ARVN $34.11
- Technical
- Relative Strength Index (RSI)
- FTK 54.95
- ARVN 58.33
- Support Level
- FTK $13.56
- ARVN $7.30
- Resistance Level
- FTK $15.27
- ARVN $7.89
- Average True Range (ATR)
- FTK 0.85
- ARVN 0.38
- MACD
- FTK -0.20
- ARVN 0.03
- Stochastic Oscillator
- FTK 40.25
- ARVN 79.41
About FTK Flotek Industries Inc.
Flotek Industries Inc is a technology-driven specialty chemistry and data company. It has two reportable segments: Its Chemistry Technologies segment includes specialty chemistries, logistics and technology services. It also include integrated oil and gas companies, oilfield services companies, independent oil and gas companies, national and state-owned oil companies, and international supply chain management companies. The Data Analytics segment provides analytical measurement solutions and deliver real-time information and insights to customers to enable optimization of operations and reduction of emissions and their carbon intensity. Key revenue comes from its Chemistry Technologies segment.
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.